Epigenetic modulation enhances immunotherapy for hepatocellular carcinoma.

CONCLUSIONS: This study demonstrates that epigenetic modulation could be a novel potential strategy to augment immunotherapy for HCC by stimulating T cell trafficking into tumor microenvironment via activation of transcriptionally repressed chemokine genes responsible for T-cell trafficking, inducing previously silent neoantigens for immune targets, and allowing tumor regression as a result. A clinical trial of this feasible combination therapy of these clinically available agents is warranted. PMID: 30626493 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30626493?dopt=Abstract

Source: Cellular Immunology - January 2, 2019 Category: Allergy & Immunology Authors: Hong YK, Li Y, Pandit H, Li S, Pulliam Z, Zheng Q, Yu Y, Martin RCG Tags: Cell Immunol Source Type: research